oncology

Having Your Melanoma Slides Re-Read by a Dermatopathologist

The value of a melanoma second opinion sits mostly in the microscope. Distinguishing an unusual mole from an early melanoma, and reading the exact depth of one, is interpretation-dependent work — and depth and stage decide the surgery and the follow-up. This is how re-reading the slides works, how often it changes the plan, and how to request your pathology for review.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What a second opinion on melanoma actually involves

A melanoma second opinion has two parts that often move separately. First, a dermatopathologist, a pathologist who did extra training specifically in reading skin, re-examines the actual glass slides from your biopsy — not just the typed report. Second, a surgical or medical oncologist reviews your stage, your margins, and whether more surgery or a sentinel lymph node biopsy is warranted. Either request stands on its own.

For melanoma, the slide re-read is usually the higher-yield of the two, because so much of what happens next is set by what the pathologist sees under the microscope. A skin biopsy second opinion does not require a new procedure — the tissue already exists, mounted on glass and stored as a paraffin block at the lab that processed it. What it requires is having that physical material sent to the reviewing pathologist, which is a request you or your doctor makes, not a second surgery. Many people ask for a dermatopathology second review at the same academic center where they are considering treatment, so the pathology and the plan are read together.

Why pathologists disagree about melanoma

Melanocytic lesions — moles, atypical moles, and melanomas — are among the most interpretation-dependent tissue in all of pathology. Two experienced pathologists can look at the same borderline slide and land in different places: an unusual but benign mole for one, an early melanoma for the other. Depth is measured in fractions of a millimetre, and features like the mitotic rate and whether the surface is ulcerated are judgment calls that carry real weight.

Re-review by a subspecialist is designed to catch these differences. In one large mandatory-review program, 1.4% of outside cases had a diagnosis changed in a way that altered treatment or prognosis 1Ref 1Kronz JD, Westra WH, Epstein JI (1999).Mandatory second opinion surgical pathology at a large referral hospital.The 1.4% rate at which mandatory second-opinion pathology re-review changed a diagnosis in a way that altered treatment or prognosis, establishing that slide re-review catches major, care-changing errors at a low but consequential rate., and a year-long review of second-opinion pathology found major, management-changing discordance in about 1% of cases, concentrated in the tissue types pathologists find hardest 2Ref 2Farooq A, et al. (2021).Assessing the value of second opinion pathology review.The roughly 1% rate of major, management-changing discordance on second-opinion pathology review, and that discordance concentrates in the tissue types pathologists find hardest to interpret.. The pattern is sharpest for borderline lesions. When pathologists were asked to interpret borderline breast biopsies, they agreed with an expert reference on atypia only 48% of the time 3Ref 3Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson ANA, Nelson HD, Pepe MS, Allison KH, Schnitt SJ, O'Malley FP, Weaver DL (2015).Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens.That pathologists' agreement on borderline lesions is low — 48% concordance with an expert reference on breast atypia — illustrating why specimens near a diagnostic boundary benefit from expert re-review. — a reminder that the closer a specimen sits to a diagnostic boundary, the more a second read matters. Melanocytic lesions sit on exactly that kind of boundary.

How often does re-reading the slides change anything?

Most of the time a re-read confirms the original diagnosis, and that confirmation is itself worth having — it is one of the main reasons people ask. When something does change, the change is more often in the details that drive treatment than a wholesale reversal of the diagnosis.

In a review of newly diagnosed cancer cases, second opinions produced a clinically meaningful change in about 35%, and most of those changes happened even when the original diagnosis was confirmed 4Ref 4Lipitz-Snyderman A, et al. (2023).Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations.That about 35% of second opinions in newly diagnosed cancer produced a clinically meaningful change, most of which occurred even when the original diagnosis was confirmed — the value is largely in treatment and staging refinement. — landing in the staging, the margins, or the treatment plan rather than the name of the disease. For melanoma that can mean a revised Breslow depth, a mitotic count that shifts the stage, or a different recommendation about sentinel node sampling. These are the kinds of second opinions changing diagnoses less than they change what is done about them, which is usually where the value is.

Does the imaging need a second look too?

For thin, early melanomas, imaging usually is not part of the workup at all — the slide is the whole story. For thicker or node-positive melanoma, where scans are done to look for spread, a second read of the imaging can add something the pathology review does not.

Subspecialist re-reading of outside PET-CT scans produced at least one discordant opinion about whether a finding was cancer in 13% of examinations, and where the truth was later known the subspecialist read was correct in 25 of 28 cases 5Ref 5Ulaner GA, Mannelli L, Dunphy M (2017).Value of second-opinion review of outside institution PET-CT examinations.That subspecialist re-reading of outside PET-CT scans produced discordant opinions of malignancy in 13% of examinations and was correct in 25 of 28 cases where the truth was later known — imaging re-review adds value beyond pathology.. That is why a full second opinion on a higher-stage melanoma often bundles the pathology and imaging for review together: the pathologist re-reads the tissue, and a radiologist re-reads the scans, so the stage rests on two fresh sets of eyes rather than one.

How to get your slides sent for review

The reviewing pathologist needs the physical slides, and sometimes the paraffin block, from the lab that first processed your biopsy — a report alone cannot be re-read. The single most useful thing to gather is the pathology material itself: the slides, the block, and the original report, released from the originating lab to the reviewing center. Labs keep these on file and release them on request, usually to a doctor or directly to you.

A workable set of records for a second opinion includes the biopsy pathology report, the slides and block, any operative or clinic notes describing the lesion, and copies of any scans on a disc rather than only the written result. Gathering records for a second opinion is administrative, not medical, and patients are entitled to copies of their records and pathology materials 6Ref 6American Cancer Society (2024).Seeking a Second Opinion.That seeking a second opinion is a normal, expected part of cancer care, that most doctors support it, and that patients are entitled to copies of their records and pathology materials.. Building this second opinion records checklist early tends to be the slowest step, so people often start it the same week they decide to seek a review.

Will asking offend your dermatologist or oncologist?

It is a common worry and, in practice, an unfounded one. Seeking a second opinion is a normal, expected part of cancer care, and most doctors both support it and are used to arranging it 6Ref 6American Cancer Society (2024).Seeking a Second Opinion.That seeking a second opinion is a normal, expected part of cancer care, that most doctors support it, and that patients are entitled to copies of their records and pathology materials.. A good clinician reads a request for a second opinion as diligence, not distrust, and many will help send the slides themselves.

The fear tends to be loudest right after a melanoma diagnosis, when the ground already feels unsteady. Framing the request plainly usually defuses it: many people simply say they want the slides re-read before committing to surgery, and ask their doctor to help route the material. There is no need to justify the decision beyond wanting to be sure.

When a melanoma second opinion is best timed

The most useful moment is usually before the definitive surgery — the wide local excision and any sentinel lymph node biopsy — because those operations are sized to the depth and stage the pathologist reports. If a re-read is going to change the depth or the node decision, it is far better to know beforehand than to have operated to the wrong plan.

That said, timing is a balance, not a race. For a thin, clearly diagnosed melanoma, a week or two to arrange a review changes nothing about the outcome. For a higher-risk lesion, the reasonable approach is to request the review promptly and in parallel rather than pausing all care to wait for it. This is the same logic behind any cancer second opinion: the goal is to get the plan right, not to add delay for its own sake.

Common questions

Yes. Because melanocytic lesions are interpretation-dependent, a subspecialist re-reading the same slides can revise the depth, the mitotic count, the margins, or occasionally whether the lesion is melanoma at all. Most re-reads confirm the original, but the ones that change something often change the stage or the surgical plan, which is exactly why the review is worth doing before definitive treatment.

The reading itself is quick — often days once the pathologist has the material. The slow part is administrative: requesting the slides and block from the originating lab and having them shipped to the reviewing center. Starting that release request early, ideally the same week you decide to seek a second opinion, is what keeps the whole process from stretching out.

A re-read needs the actual slides, and sometimes the paraffin block — the report is one pathologist's conclusion, not the evidence. The whole point of a second opinion is that a different pathologist looks at the tissue directly. A reviewing center will ask the originating lab to release the physical material; the written report alone cannot be independently re-interpreted.

Many plans cover a second opinion on a serious diagnosis, and pathology re-review is usually billed like any consultation. Coverage varies by plan, so it is worth asking your insurer what is included and whether the reviewing center is in-network. The cost of shipping slides is typically small, and some academic programs fold it into the consultation.

Breslow depth is how far, in millimetres, the melanoma has grown down into the skin, measured on the slide. It is one of the strongest drivers of stage, of how wide the surgery needs to be, and of whether a sentinel lymph node biopsy is recommended. Because it is measured by eye, a fraction of a millimetre can shift the plan — which is why the re-read matters.

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a melanoma change should not wait for a second opinion

—A mole or biopsy scar that is bleeding, crusting, or visibly growing over days to weeks rather than months
—A new firm lump in the skin near the original melanoma, or a swollen lymph node in the neck, armpit, or groin
—A previously removed melanoma site that develops new pigment, a raised nodule, or an open sore that will not heal

This article explains how a melanoma second opinion works and is general education, not a diagnosis or treatment plan for your specific case. A dermatopathologist reads slides; a page cannot. Decisions about surgery, staging, and follow-up belong to you and the clinicians reviewing your actual pathology and imaging.

References

1.Kronz JD, Westra WH, Epstein JI (1999). Mandatory second opinion surgical pathology at a large referral hospital. Cancer. doi:10.1002/(SICI)1097-0142(19991201)86:11<2426::AID-CNCR34>3.0.CO;2-3 ✓The 1.4% rate at which mandatory second-opinion pathology re-review changed a diagnosis in a way that altered treatment or prognosis, establishing that slide re-review catches major, care-changing errors at a low but consequential rate.
2.Farooq A, et al. (2021). Assessing the value of second opinion pathology review. International Journal for Quality in Health Care. doi:10.1093/intqhc/mzab032The roughly 1% rate of major, management-changing discordance on second-opinion pathology review, and that discordance concentrates in the tissue types pathologists find hardest to interpret.
3.Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson ANA, Nelson HD, Pepe MS, Allison KH, Schnitt SJ, O'Malley FP, Weaver DL (2015). Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens. JAMA. doi:10.1001/jama.2015.1405 ✓That pathologists' agreement on borderline lesions is low — 48% concordance with an expert reference on breast atypia — illustrating why specimens near a diagnostic boundary benefit from expert re-review.
4.Lipitz-Snyderman A, et al. (2023). Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations. Cancer Medicine. doi:10.1002/cam4.5598 ✓That about 35% of second opinions in newly diagnosed cancer produced a clinically meaningful change, most of which occurred even when the original diagnosis was confirmed — the value is largely in treatment and staging refinement.
5.Ulaner GA, Mannelli L, Dunphy M (2017). Value of second-opinion review of outside institution PET-CT examinations. Nuclear Medicine Communications. doi:10.1097/MNM.0000000000000647 ✓That subspecialist re-reading of outside PET-CT scans produced discordant opinions of malignancy in 13% of examinations and was correct in 25 of 28 cases where the truth was later known — imaging re-review adds value beyond pathology.
6.American Cancer Society (2024). Seeking a Second Opinion. American Cancer Society (cancer.org). link ✓That seeking a second opinion is a normal, expected part of cancer care, that most doctors support it, and that patients are entitled to copies of their records and pathology materials.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library